Form 990 for tax year 2023
Filed by ALTERNATIVES FOR RESEARCH AND DEVELOPMENT FOUNDATION.
Totals
- Total revenue
- $750,868
- Total expenses
- $634,425
- Contributions and grants received
- $77,619
- Grants paid
- $266,937
- Program service revenue
- $0
- Investment income
- $673,249
- Other revenue
- $0
- Total assets, end of year
- $14,204,946
- Total liabilities, end of year
- $16,178
- Net assets or fund balances, end of year
- $14,188,768
- Program services expenses (Part IX)
- $478,143
- Management and general expenses
- $152,646
- Fundraising expenses
- $3,636
- Program service expenses (Part III)
- $478,143
Program services were 75.4% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1f · All other contributions, gifts and grants
$77,619
-
3 · Investment income
total $185,725 · excluded $185,725
-
7a · Gross sales of assets other than inventory
securities $2,634,274
-
7b · Less cost or other basis and sales expenses
securities $2,146,750
-
7c · Gain or loss
securities $487,524
-
7d · Net gain or loss
total $487,524 · excluded $487,524
Functional expenses
Part IX, the statement of functional expenses.
-
1 · Grants to domestic organizations and governments
total $196,937 · program services $196,937
-
3 · Grants to foreign organizations and individuals
total $70,000 · program services $70,000
-
5 · Compensation of officers, directors and key employees
total $20,000 · program services $20,000
-
7 · Other salaries and wages
total $14,071 · program services $3,443 · management and general $8,265 · fundraising $2,363
-
9 · Other employee benefits
total $10,267 · program services $6,504 · management and general $2,820 · fundraising $943
-
10 · Payroll taxes
total $3,123 · program services $2,061 · management and general $821 · fundraising $241
-
11c · Fees: accounting
total $17,355 · management and general $17,355
-
11f · Fees: investment management
total $121,976 · management and general $121,976
-
11g · Fees: other
total $136,956 · program services $136,834 · management and general $93 · fundraising $29
-
13 · Office expenses
total $10,689 · program services $10,036 · management and general $593 · fundraising $60
-
16 · Occupancy
total $18,352 · program services $17,739 · management and general $613
-
19 · Conferences, conventions and meetings
total $12,809 · program services $12,809
-
22 · Depreciation, depletion and amortization
total $600 · program services $600
-
23 · Insurance
total $141 · program services $106 · management and general $35
-
24a · Other expenses: RESEARCH AND INFORMATIO
total $1,009 · program services $984 · management and general $25
-
24b · Other expenses: POSTAGE AND SHIPPING
total $140 · program services $90 · management and general $50
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $690,750 · end of year $80,052
-
2 · Savings and temporary cash investments
beginning of year $403,362 · end of year $1,044,307
-
4 · Accounts receivable
end of year $18,075
-
9 · Prepaid expenses and deferred charges
beginning of year $4,212 · end of year $3,358
-
10a · Land, buildings and equipment: cost or other basis
$12,396
-
10b · Land, buildings and equipment: accumulated depreciation
$10,896
-
10c · Land, buildings and equipment, net
beginning of year $2,100 · end of year $1,500
-
11 · Investments: publicly traded securities
beginning of year $10,366,590 · end of year $12,634,377
-
15 · Other assets
beginning of year $408,778 · end of year $423,277
-
17 · Accounts payable and accrued expenses
beginning of year $72 · end of year $7,496
-
25 · Other liabilities
beginning of year $42,392 · end of year $8,682
-
27 · Net assets without donor restrictions
beginning of year $10,943,315 · end of year $13,229,485
-
28 · Net assets with donor restrictions
beginning of year $890,013 · end of year $959,283
Mission and programs · 2023
Mission
THE MISSION OF THE ARDF IS TO FUND AND PROMOTE THE DEVELOPMENT, VALIDATION AND ADOPTION OF NON-ANIMAL METHODS IN BIOMEDICAL RESEARCH, PRODUCT TESTING, AND EDUCATION.
Activities or mission (Part I)
ARDF PROMOTES AND DEVELOPS ALTERNATIVE SCIENTIFIC SOLUTIONS TO THE PROBLEM OF ANIMAL TESTING.
-
THE "ANNUAL OPEN" GRANT PROGRAM FUNDS INNOVATIVE ALTERNATIVE METHODS TO REDUCE OR REPLACE ANIMAL USE IN RESEARCH AND TESTING.2023'S FUNDED PROJECTS WERE FOR SCIENTIFIC RESEARCH: 1.) USING HUMAN LUNG SLICES TO STUDY THE RELATIONSHIP BETWEEN CIGARETTE SMOKE AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), AND TO TEST DRUG CANDIDATES FOR TREATING COPD. 2.) USING HUMAN GINGIVAL SLICES TO DEVELOP A NON-ANIMAL MODEL FOR STUDYING ORAL INFLAMMATORY DISEASES. 3.) USING HUMAN BRAIN ORGANOIDS TO EXAMINE THE EFFECTS OF SEX HORMONES ON NEURODEVELOPMENT IN ORDER TO UNDERSTAND HOW ENDOCRINE DISRUPTORS CAN ALTER IMPORTANT PROCESSES IN THE DEVELOPING BRAIN. 4.) HUMAN-BASED IN VITRO 3D MODEL OF BONE FRACTURE HEALING TO STUDY THE INITIAL BLEEDING AND HEALING PROCESSES THAT OCCUR DURING BONE FRACTURE. 5.) PANCREATIC ISLET ORGANOIDS-ON-A-CHIP SYSTEM TO STUDY TYPE 1 DIABETES, PROVIDING A NOVEL PLATFORM THAT COULD REPLACE THE USE OF ANIMALS IN IDENTIFYING NEW TREATMENTS FOR THIS CHALLENGING DISEASE. 6.) A CARDIAC CELL MODEL TO EXAMINE DRUG INTERACTIONS WITH ALCOHOL, SINCE CARDIOTOXICITY IS THE LEADING REASON DRUGS FAIL TO SUCCESSFULLY MOVE FROM ANIMAL STUDIES TO HUMAN TREATMENT. 7.) USING A LIVER-BASED CELL CULTURE SYSTEM TO STUDY THE POTENTIALLY TOXIC EFFECTS OF MICROPLASTICS ON LIVER TISSUE. THIS YEAR'S FOCUS ON DEVELOPING MODELS TO AID DEVELOPMENT OF TREATMENTS UNDERSCORES THE TREMENDOUS POTENTIAL OF IN VITRO MODELS FOR BIOMEDICAL RESEARCH. BY SUPPORTING RESEARCH TO DEVELOP ALTERNATIVE, ANIMAL-FREE MODELS, ARDF CONTINUES TO ADVANCE BOTH ANIMAL WELFARE AND HUMAN HEALTH.ARDF ALSO SPONSORED SCIENTIFIC MEETINGS, AND EDUCATION AND OUTREACH ON ALTERNATIVE METHODS TO ACCELERATE UNDERSTANDING AND COLLABORATION.
Expenses $478,143 · Grants $266,937
As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
Sue A LearySUE A LEARY
PRESIDENT
- Total calculated
- $91,145
- From this org
- $20,000
- From related orgs
- $65,203
- Other
- $5,942
- Hours/week
- 12 + 35 related
-
Nadia S AdawiNADIA S ADAWI
BOARD MEMBER
- Total calculated
- $0
- Hours/week
- 0.5 + 0.5 related
-
Robert FinnROBERT FINN
BOARD MEMBER
- Total calculated
- $0
- Hours/week
- 0.5 + 0.5 related
-
Francis KrafchikFRANCIS KRAFCHIK
BOARD MEMBER
- Total calculated
- $0
- Hours/week
- 0.5 + 0.5 related
-
Joseph LudwigJOSEPH LUDWIG
VICE PRESIDENT
- Total calculated
- $0
- Hours/week
- 0.5 + 1 related
-
Aaron McIntyreAARON MCINTYRE
TREASURER
- Total calculated
- $0
- Hours/week
- 0.5 + 1 related
-
Denise CowieDENISE COWIE
SECRETARY
- Total calculated
- $0
- Hours/week
- 0.5 + 1 related
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those.
Grants on this return
-
UNIVERSTY OF CONNECTICUT HEALTH CENTER
$40,000
DR. KSHITIZ RESEARCH GRANT - HIGHLY MATURED HUMAN CARDIAC MODELS TO MEASURE CARDIOTOXICITY
-
UNIVERSTY OF WASHINGTON OFFICE OF SPONSORED PROGRAMS
$40,000
DR. VINCENZO CIRULLI RESEARCH GRANT - MODELING DIABITIES IN AN ORGANOID ON CHIP PLATFORM
-
DR. MAREN SCHENKE RESEARCH GRANT - ADVANCED NEUROTOXICITY TESTING WITH AN IN VITRO MODEL OF SEX DIFFERENCES
-
ADA SCIENCE & RESEARCH INSTITUTE LLC
$40,000
DR. QUINN EASTER RESEARCH GRANT - PRECISION-CUT GINGIVAL SLICES AS AN ANIMAL-FREE MODEL OF ORAL INFLAMMATION
-
JOHNS HOPKINS UNIVERSITY JHURA
$40,000
DR. VENKATARAMANA SIDHAYE RESEARCH GRANT - DEVELOPING MODEL USING HUMAN LUNG SLICES TO STUDY COPD AND POTENTIAL DRUG THERAPEUTICS
-
SUPPORT OF IIVS EDUCATION AND OUTREACH PROGRAMS
Related organizations on this return
Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.
-
AMERICAN ANTI-VIVISECTION SOCIETY
501(C)(3) · EDUCATE THE PUBLIC ON PROBLEMS OF ANIMAL EXPERIMENTATION · PA
Directly controlled by NONE
Provenance
- Return type
- form_990
- Tax year
- 2023
- Filed
- 13 May 2024
- IRS schema version
- 2023v5.0
- Source object
- 202441349349305714
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.